Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
baiH (7-β dehydratase): Downstream of baiG, the baiH gene encodes a 7-β dehydratase that has NADH:flavin oxidoreductase activity. This enzyme removes the carbon-carbon double bond introduced by baiCD. The connection between 7-β dehydratase and NADH was illuminated in a study that introduced a purified version of this protein into C. scindens, resulting in a decrease in the ratio of oxidized to reduced bile acid intermediates in the 7ɑ-dehydroxylation pathway. Since NAD+/NADH are electron carriers, these researchers assumed that this change in oxidized:reduced intermediate ratio indicated that 7-β dehydratase affected NADH levels. baiI (Δ-ketosteroid isomerase/7-β dehydratase): baiI, the furthest downstream gene of the bai operon, encodes for a protein that does not appear to be required for 7ɑ-dehydroxylation despite being highly conserved among different strains of Clostridium scindens. The classification of this protein is also under scrutiny, as some researchers believe it to have Δ-ketosteroid isomerase functionality while others believe it is a 7-β dehydratase like baiH.
Mass spectrometry is used where very high sensitivity is required and is sometimes used as a back-end process after gas liquid chromatography for detecting trace organic chemicals. Depending on the components, different methods are applied to determine the quantities or ratios of the components. While some methods can be performed with standard laboratory equipment, others require advanced devices, such as inductively coupled plasma mass spectrometry (ICP-MS).
=== Immune system === Vitamin D receptors are found in cell types involved in immunity. Functions are not understood. Some autoimmune and infectious diseases are associated with vitamin D deficiency, but either there is no evidence that supplementation has a benefit or not, or for some, evidence indicating there are no benefits.
Sources: en.wikipedia.org
=== TRPV1 === AM404 is also a TRPV1 agonist and inhibitor of cyclooxygenase COX-1 and COX-2, thus attenuating prostaglandin synthesis. The anticonvulsant action of AM404 is mediated through TRPV1, according to Suemaru et al. (2018), rebutting a previous explanation involving CB1 receptors.
Nihonium is a synthetic chemical element; it has symbol Nh and atomic number 113. It is extremely radioactive: its most stable known isotope, nihonium-286, has a half-life of about 10 seconds. In the periodic table, nihonium is a transactinide element in the p-block. It is a member of period 7 and group 13. Nihonium was first reported to have been created in experiments carried out between 14 July and 10 August 2003, by a Russian–American collaboration at the Joint Institute for Nuclear Research (JINR) in Dubna, Russia, working in collaboration with the Lawrence Livermore National Laboratory in Livermore, California, and on 23 July 2004, by a team of Japanese scientists at Riken in Wakō, Japan. The confirmation of their claims in the ensuing years involved independent teams of scientists working in the United States, Germany, Sweden, and China, as well as the original claimants in Russia and Japan. In 2015, the IUPAC/IUPAP Joint Working Party recognised the element and assigned the priority of the discovery and naming rights for the element to Riken. The Riken team suggested the name nihonium in 2016, which was approved in the same year. The name comes from the common Japanese name for Japan (日本, Nihon). Very little is known about nihonium, as it has been made only in very small amounts that decay within seconds. The anomalously long lives of some superheavy nuclides, including some nihonium isotopes, are explained by the island of stability theory.
Fried ice cream is a dessert made of a scoop of ice cream that is frozen hard, then breaded or coated in a batter before being quickly deep-fried, creating a warm, crispy shell around the still-cold ice cream. It is common in Chinese and Mexican cuisine.
=== Bibliography === "Annex A – Estate Baseline – 2009" (PDF). Defence Estates Development Plan (DEDP) 2009. GOV.UK (Report). Ministry of Defence. 3 July 2009. Retrieved 30 March 2023. Halley, James J (1988). RAF Squadrons. The Squadrons of the Royal Air Force & Commonwealth 1918–1988. Tonbridge, UK: Air Britain (Historians). ISBN 0-85130-164-9. Jackson, Paul (1986). Britain's Armed Forces Today: 4 RAF Germany. Shepperton, UK: Ian Allan. ISBN 0-7110-1579-1. Jefford, C. G. (1988). RAF Squadrons. A comprehensive record of the movement and equipment of all RAF squadrons and their antecedents since 1912. Shrewsbury, UK: Airlife. ISBN 1-85310-053-6. Langford, F. (1991). The Dorset Year Book - 1991. Dorset, UK: The Society Of Dorset Men. March, Peter R. (1992). Royal Air Force Yearbook 1992. Fairford, UK: Royal Air Force Benevolent Fund. March, Peter R. (1998). Royal Air Force Yearbook 1998. Fairford, UK: Royal Air Force Benevolent Fund. Sturtivant, Ray; Hamlin, John (2007). Royal Air Force flying training and support units since 1912. Tonbridge, UK: Air-Britain (Historians). ISBN 978-0851-3036-59.
Sources: en.wikipedia.org
=== Miscellaneous === Galactogogues such as the peripherally selective D2 receptor antagonist and prolactin releaser domperidone can be used to induce lactation in transgender women who wish to breastfeed. An extended period of combined estrogen and progestogen therapy is necessary to mature the lobuloalveolar tissue of the breasts before this can be successful. There are several published reports of lactation and/or breastfeeding in transgender women. The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8), released in September 2022, recommends against therapeutic strategies including supraphysiological estradiol levels (>200 pg/mL), use of progesterone (including rectal progesterone), use of bicalutamide, and monitoring of the ratio of estrone to estradiol. This is due to lack of data to support these approaches in transfeminine people as well as potential risks. The WPATH SOC8 also recommends against the use of 5α-reductase inhibitors such as finasteride in transfeminine people.
== List of hosts == Amur Cossack Host (1860–1918) Astrakhan Cossack Host (1737–1920) Azov Cossack Host (1832–1862) Baikal Cossack Host (1851-1920) Bashkir Host (1798-1865) Black Sea Cossack Host (1787–1864) Buh Cossack Host (1769–1817) Caucasus Line Cossack Host (1832–1860) Danube Cossack Host (1828–1868), an Imperial Russian Cossack Host formed from descendants of the Zaporozhian Cossacks Don Cossack Host (1570-1918, reconstituted in 1992) Greben Cossacks Host (1711–1745–1845-60–1920, reconstituted in 1992) Kuban Cossack Host (1860–1920, reconstituted in 1992) Orenburg Cossack Host (1755–1920) Semiryechye Cossack Host (1867–1920) Siberian Cossack Host (1582-1918) Terek Cossack Host (1577–1792–1860–1920, reconstituted in 1992) Transbaikal Cossack Host (1851–1920) Ural Cossack Host (c. 14th century-end–1920) Ussuri Cossack Host (1889–1922, re-established in 1990) Volga Cossack Host (1734–1777) Zaporozhian Host (1572/1649–1775), of the Zaporozhian Cossacks who lived in Zaporizhia, Dnieper Ukraine, during the 16th — 18th centuries.
Many soluble salts of acid dyes synthesized for textile-related purposes were transformed into insoluble salts or lake pigments by reaction with water-soluble salts of calcium, barium or lead, whereas basic dyes were treated with tannins or antimony potassium tartrate to yield pigments.
Minor histocompatibility antigen (also known as MiHA) are peptides presented on the cellular surface of donated organs that are known to give an immunological response in some organ transplants. They cause problems of rejection less frequently than those of the major histocompatibility complex (MHC). Minor histocompatibility antigens (MiHAs) are diverse, short segments of proteins and are referred to as peptides. These peptides are normally around 9-12 amino acids in length and are bound to both the major histocompatibility complex (MHC) class I and class II proteins. Peptide sequences can differ among individuals and these differences arise from SNPs in the coding region of genes, gene deletions, frameshift mutations, or insertions. About a third of the characterized MiHAs come from the Y chromosome. Prior to becoming a short peptide sequence, the proteins expressed by these polymorphic or diverse genes need to be digested in the proteasome into shorter peptides. These endogenous or self peptides are then transported into the endoplasmic reticulum with a peptide transporter pump called TAP where they encounter and bind to the MHC class I molecule. This contrasts with MHC class II molecules's antigens which are peptides derived from phagocytosis/endocytosis and molecular degradation of non-self entities' proteins, usually by antigen-presenting cells. MiHA antigens are either ubiquitously expressed in most tissue like skin and intestines or restrictively expressed in the immune cells.
== Books == The Malay Dilemma (1970) ISBN 981-204-355-1 The Challenge (1986) ISBN 967-978-091-0 Regionalism, Globalism, and Spheres of Influence: ASEAN and the Challenge of Change into the 21st century (1989) ISBN 981-303-549-8 Mahathir, Great Malaysian Hero (1990) ISBN 983-9683-00-4 The Asia That Can Say No (1994) ISBN 433-405-217-7 The Pacific Rim in the 21st century (1995) The Challenges of Turmoil (1998) ISBN 967-978-652-8 The Way Forward (1998) ISBN 0-297-84229-3 A New Deal for Asia (1999) Islam & The Muslim Ummah (2001) ISBN 967-978-738-9 Globalisation and the New Realities (2002) Reflections on Asia (2002) ISBN 967-978-813-X The Malaysian Currency Crisis: How and why it Happened (2003) ISBN 967-978-756-7 Mahathir: 22 Years, 22 Voices (2003) Dr Mahathir Mohamad - Father of Sports Development (2003) Achieving True Globalisation (2004) ISBN 967-978-904-7 Islam, Knowledge, and Other Affairs (2006) ISBN 983-3698-03-4 Principles of Public Administration: An Introduction (2007) ISBN 978-983-195-253-5 Chedet.com Blog Merentasi Halangan (Bilingual) (2008) ISBN 967-969-589-1 A Doctor in the House: The Memoirs of Tun Dr Mahathir Mohamad (2011) ISBN 9789675997228 Doktor Umum: Memoir Tun Dr. Mahathir Mohamad (2012) ISBN 9789674150259 Blogging to Unblock (Book 2): A Citizen's Rights (2013) ISBN 9789679696288 Dr. M: Apa Habaq Orang Muda? (2016) ISBN 9789671367995 Capturing Hope: The Struggle Continues for a New Malaysia (2021) ISBN 9789672923183 A Conversation with Tun Dr Mahathir bin Mohamad: A Legacy of Leadership and Vision (2025) ISBN 9789670821436
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.